IGF1 and glioma: Additionally, miR-29s have also been shown to arrest the cell cycle at G0/G1 phases in gliomas [32] and breast cancer [46], and the G1-S phase in acute myeloid leukemia (AML) [47] by targeting cell division cycle 42 (CDC42) and cyclin D2 (CCND2), respectively; or to suppress tumor growth by repressing angiogenesis genes such as vascular endothelial growth factor (VEGF) [48,49] and insulin-like growth factor 1 (IGF-1) [50] in osteosarcoma and gastric cancer cells.